Lake Street Reiterates Buy on Castle Biosciences, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten has reiterated a 'Buy' rating on Castle Biosciences (NASDAQ:CSTL) and maintained a price target of $32.
July 07, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lake Street analyst has reiterated a 'Buy' rating on Castle Biosciences and maintained a price target of $32.
The 'Buy' rating from Lake Street analyst indicates a positive outlook for Castle Biosciences. The maintained price target of $32 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100